Curman, Philip
Jebril, William
Larsson, Henrik
Bachar-Wikstrom, Etty
Cederlöf, Martin
Wikstrom, Jakob D.
Funding for this research was provided by:
Hudfonden
Swedish Science Council
Svenska Sällskapet för Medicinsk Forskning
Leo foundation
ALF medicin Stockholm
Jeanssons stiftelse
Marcus och Amalia Wallenbergs minnesfond
Tore Nilssons Stiftelse
Karolinska Institute
Article History
Received: 17 May 2023
Accepted: 21 March 2024
First Online: 26 March 2024
Competing interests
: Henrik Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. Henrik Larsson is editor-in-chief of JCPP Advances. The other authors have no competing interests.